These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 27058929)
1. Imprecision Medicine: A One-Size-Fits-Many Approach for Muscle Dystrophy. Breitbart A; Murry CE Cell Stem Cell; 2016 Apr; 18(4):423-4. PubMed ID: 27058929 [TBL] [Abstract][Full Text] [Related]
2. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD. Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761 [TBL] [Abstract][Full Text] [Related]
3. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy. Cai A; Kong X Hum Gene Ther Methods; 2019 Jun; 30(3):71-80. PubMed ID: 31062609 [TBL] [Abstract][Full Text] [Related]
4. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping. Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778 [TBL] [Abstract][Full Text] [Related]
5. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224 [TBL] [Abstract][Full Text] [Related]
8. Functional correction of dystrophin actin binding domain mutations by genome editing. Kyrychenko V; Kyrychenko S; Tiburcy M; Shelton JM; Long C; Schneider JW; Zimmermann WH; Bassel-Duby R; Olson EN JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931764 [TBL] [Abstract][Full Text] [Related]
9. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells. Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387 [TBL] [Abstract][Full Text] [Related]
10. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Amoasii L; Long C; Li H; Mireault AA; Shelton JM; Sanchez-Ortiz E; McAnally JR; Bhattacharyya S; Schmidt F; Grimm D; Hauschka SD; Bassel-Duby R; Olson EN Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187645 [TBL] [Abstract][Full Text] [Related]
11. Cautious welcome for gene editing of Duchenne muscular dystrophy in animal model. Hawkes N BMJ; 2016 Jan; 351():h7033. PubMed ID: 26729900 [No Abstract] [Full Text] [Related]
12. The emerging role of viral vectors as vehicles for DMD gene editing. Maggio I; Chen X; Gonçalves MA Genome Med; 2016 May; 8(1):59. PubMed ID: 27215286 [TBL] [Abstract][Full Text] [Related]
13. Genetic engineering: In vivo genome editing - growing in strength. Koch L Nat Rev Genet; 2016 Mar; 17(3):124. PubMed ID: 26781811 [No Abstract] [Full Text] [Related]
14. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy. Nik-Ahd F; Bertoni C Stem Cells; 2014 Jul; 32(7):1817-30. PubMed ID: 24753122 [TBL] [Abstract][Full Text] [Related]